Realizing the Promise of Tumor Infiltrating Lymphocytes as a New Biomarker for Personalized Medicine May Require the Power and Precision of Artificial Intelligence
Restricted accessResearch articleFirst published online February, 2024
Realizing the Promise of Tumor Infiltrating Lymphocytes as a New Biomarker for Personalized Medicine May Require the Power and Precision of Artificial Intelligence
WaldmanAD, FritzJM, LenardoMJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol, 2020;20(11):651–668; https://doi.org/10.1038/s41577-020-0306-5
2.
FridmanWH, PagèsF, Sautès-FridmanC, et al.The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer, 2012;12(4):298–306; doi: 10.1038/nrc3245
3.
TumehPC, HarviewCL, YearleyJH, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014;515(7528):568–571; doi: 10.1038/nature13954
4.
Lopez de RodasM, NagineniV, RaviA, et al.Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer, 2022;10(6):e004440; doi: 10.1136/jitc-2021-004440
5.
OliveiraG, StromhaugK, KlaegerS, et al.Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature, 2021;596(7870):119–125; https://doi.org/10.1038/s41586-021-03704-y
6.
GettingerSN, ChoiJ, ManiN, et al.A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun, 2018;9(1):3196; doi: 10.1038/s41467-018-05032-8
7.
BaxiV, EdwardsR, MontaltoM, et al.Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol, 2022;35(1):23–32; doi: 10.1038/s41379-021-00919-2
8.
BaxiV, LeeG, DuanC, et al.Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol, 2022;35(11):1529–1539; doi: 10.1038/s41379-022-01119-2
9.
DuanC, MontaltoM, LeeG, et al.Abstract 2017: Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients. Cancer Res, 2020. doi:10.1158/1538-7445.am2020-2017
10.
Taylor-WeinerA, BeckA, CowanJD, et al.Machine learning-based identification of predictive features of the tumor micro-environment and vasculature in NSCLC patients using the IMpower150 study. J Clin Oncol, 2020;38; doi: 10.1200/JCO.2020.38.15_suppl.3130
11.
QamraA, SrivastavaMK, FuentesE, et al.Abstract 5705: Digital pathology based prognostic & predictive biomarkers in metastatic non-small cell lung cancer. Cancer Res, 2023;83(7 Suppl):5705; https://doi.org/10.1158/1538-7445.AM2023-5705
12.
PomponioR, TangQ, MeiA, et al.An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy. Acta Pharm Sin B, 2022;12(9):3594–3601; doi: 10.1016/j.apsb.2022.03.013
13.
BarreraC, CorredorG, ViswanathanVS, et al.Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. NPJ Precis Oncol, 2023;7(1):52; https://doi.org/10.1038/s41698-023-00403-x
14.
DingR, PrasannaP, CorredorG, et al.Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. NPJ Precis Oncol, 2022;6(1):33; doi: 10.1038/s41698-022-00277-5
15.
WangX, BarreraC, BeraK, et al.Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv, 2022;8(22):eabn3966; doi: 10.1126/sciadv.abn3966
